PPARG and Obesity: Therefore, our findings establish that specific targeting of PPARγ, CB2 and HIF pathway with VCE-004.8 may be a therapeutic approach for the management of obesity and T2D, without the harmful effects on adipogenesis and osteoblastogenesis associated with PPARγ full agonists.